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D13 protein trimers, which form an external lattice providing curvature to the membrane of vaccinia virus immature virions, are the target of
the drug rifampicin. We obtained 63 rifampicin-resistant mutants following random PCR mutagenesis of the D13L gene and 5 that arose
spontaneously. Sequencing indicated that 26 mutants contained a single, unique, amino acid substitution whereas others contained 2 or more. The
single mutations, including 6 previously identified, mapped to 24 different amino acids that were distributed over the length of the protein with the
majority clustered between amino acids 17 to 33, 222 to 243 and 480 to 488. Two or three different substitutions occurred in six of the 24 amino
acids. Representative mutant viruses of each cluster replicated to wild-type levels in the absence of rifampicin and nearly two logs higher than
wild-type in the presence of drug. The large number and fitness of the mutations are remarkable in view of the extreme sequence conservation
(99–100% amino acid identity amongst all orthopoxviruses). Clustering of mutations could suggest the presence of a rifampicin-binding pocket
comprised of discontinuous regions of D13.
Published by Elsevier Inc.Keywords: Poxvirus; Drug-resistant mutants; RifampicinIntroduction
Poxviruses are large, enveloped DNA viruses that replicate
and assemble in the cytoplasm of infected cells. Crescent-shaped
membranes and spherical immature virions (IVs) are the first viral
forms that can be recognized by electron microscopy in cells
infectedwith vaccinia virus (VACV) and other poxviruses (Dales
and Siminovitch, 1961; de Harven and Yohn, 1966). The
curvature of the crescent and IV membranes is determined by
an external lattice comprised of trimers of a 63-kDa protein
encoded by theD13L (VACWR118) gene (Heuser, 2005; Szajner
et al., 2005). During the subsequent stage of morphogenesis, the
IV condenses into the infectious brick-shaped intracellular
mature virion (MV) that no longer displays the lattice, indicating⁎ Corresponding author.
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doi:10.1016/j.virol.2006.09.031that D13 acts as a temporary scaffold. D13 is conserved in all
poxviruses and a segment has a low but significant sequence
identity with capsid proteins of certain other large DNA viruses
(Iyer et al., 2001), leading to the idea that poxvirus morphogen-
esis may recapitulate evolution from an ancestral icosahedral
virus to a more complex form (Szajner et al., 2005).
The external lattice, originally thought to be a spicule layer,
does not form on the surface of viral membranes when cells are
infected with VACV in the presence of the drug rifampicin
(Grimley et al., 1970; Moss et al., 1969b; Nagayama et al.,
1970), a semisynthetic antibiotic with a molecular weight of 823
derived from Streptomyces mediterranei. Instead, irregular viral
membranes surrounding masses of electron dense material are
observed. Although rifampicin binds to the β subunit of the
DNA-dependent RNA polymerase of bacteria and inhibits
transcription, the drug has little or no effect on transcription of
vaccinia virus, which encodes its own rifampicin-insensitive
RNA polymerase (Moss et al., 1969a). Instead, there is
considerable evidence that the D13 scaffold protein is the target
of rifampicin: VACV mutations that confer resistance to
rifampicin map exclusively to the D13L gene (Baldick and
Fig. 2. Frequency of rifampicin-resistant mutants following transfection of
D13L DNAwith site-specific mutations. Plasmid pJAG9.4 containing wild-type
D13L gene and flanking DNA or the same plasmid with site-specific mutations,
corresponding to those found in rifampicin-resistant mutants generated by
random PCR mutagenesis, were transfected into BS-C-1 cells infected with
VACV WR. After 24 h, the titer of rifampicin-resistant virus in each transfected
culture was determined by plaque assay. The relative numbers of rifampicin-
resistant plaques were determined by dividing the number detected after
transfection of each mutated plasmid by the number obtained by transfection of
the wild-type gene in the same experiment. Bars represent standard error (N=4).
228 J.C. Charity et al. / Virology 359 (2007) 227–232Moss, 1987; McNulty-Kowalczyk and Paoletti, 1993; Tartaglia
et al., 1986); repression of D13L expression blocks virus
assembly, resulting in the formation of irregular membranes that
closely resemble those formed in the presence of rifampicin
(Zhang and Moss, 1992); and D13 accumulates in large
cytoplasmic masses in the presence of rifampicin, preventing
association with crescent and IV membranes (Miner and Hruby,
1989; Mohandas and Dales, 1995; Sodeik et al., 1994).
In the present study, random PCR mutagenesis was used to
generate a large library of D13 mutations that confer resistance
to rifampicin. The number and fitness of the mutations are
remarkable in view of the sequence conservation of the protein
(99–100% identity in orthopoxviruses). Most of the mutations
clustered within short segments at the N- and C-termini and also
in the central region of D13, suggesting a putative rifampicin-
binding pocket comprised of discontinuous regions of D13.
Results
Isolation of rifampicin-resistant mutants with missense
substitutions in D13
Random PCR mutagenesis was performed under conditions
intended to introduce 0 to 3 nucleotide changes into each copy of
the D13L gene. The DNAwas then transfected into BS-C-1 cells
that had been infected with VACV strain WR. After harvesting
the infected cells, lysates were applied to fresh monolayers in the
presence of rifampicin (100 μg/ml). Virus was picked from the
drug-resistant plaques and subjected to a second round of plaque
purification in the presence of the same concentration of
rifampicin. Stocks of each rifampicin-resistant virus were then
prepared and the D13L gene of each was sequenced. Of 63
rifampicin-resistant isolates, 25 had single missense mutations
in the D13L gene and 22 of these were unique. The other
rifampicin-resistant mutants had two or more substitutions in the
D13L gene. In addition, we isolated five spontaneous
rifampicin-resistant mutants after one amplification passage of
individual virus plaques; each had a single amino acid
substitution in the D13L gene and four of these were unique
relative to the ones obtained by PCR mutagenesis. The locations
of the 26 new single mutations in addition to 6 previously
identified spontaneous mutations differing from the above are
shown in Fig. 1. The 32 mutations occurred in 24 amino acids (6Fig. 1. Amino acid substitutions that confer resistance to rifampicin. The position nu
amino acid is to the left of the number and the substitution(s) on the right. Spontaneou
of the D13L gene.of the amino acids had 2 or 3 different substitutions), which were
distributed between amino acids 17 to 94, 175 to 314 and 429 to
488. Within these regions, clustering of mutations occurred
between amino acids 17 to 33, 222 to 243 and 480 to 488.
Demonstration that the D13 mutations confer rifampicin
resistance
The occurrence of D13 mutations in many of the rifampicin-
resistant VACV mutants could have been coincidental, since
the infected cells were transfected with DNA containing the
randomly mutagenized D13 gene. To determine whether the
D13 amino acid substitutions confer rifampicin resistance, we
made specific mutations in plasmid pJAG9.4, which contains
the wild-type D13 gene and approximately 200 bp of flanking
sequence on each side. Cells were infected with VACV strain
WR and transfected with either non-mutagenized or muta-
genized pJAG9.4. After 24 h, the cells were harvested and the
number of rifampicin-resistant mutants was determined by
plaque assay. Data from four replicate transfections are shown
in Fig. 2. The number of resistant mutants obtained wasmber of each amino acid conferring rifampicin resistance is shown. The original
s mutations are underlined; others were obtained after random PCR mutagenesis
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D13 genes than with the wild-type gene, confirming the rela-
tionship of D13 amino acid substitutions with rifampicin
resistance. The difference in frequency of rifampicin-resistant
mutants did not correlate with position of the gene and could
have been related to the DNA preparations or other factors.
Plaque morphology of mutant viruses
In the absence of rifampicin, the plaque sizes of most mu-
tants were similar to each other and to wild-type virus. Two
exceptions were R234E and N480S; after 48 h the plaques were
∼75% of the size of wild-type virus plaques. In the presence of
100 μg per ml of rifampicin, the wild-type virus made no
plaques whereas the numbers of plaques of the mutants were
unaffected. However, the plaques of the mutant viruses wereFig. 3. Plaque morphology of rifampicin-resistant mutants. Plaques that formed in 2
resistant mutants and wild-type VACV in the presence (+Rif) and absence (−Rif) of
photographed. Mutants are designated by the codon substitution in the D13L gene.smaller in the presence of rifampicin than in its absence and
varied slightly in size. Plaques of wild-type virus and repre-
sentative mutants mapping to different locations in the D13
open reading frame are shown in Fig. 3.
Virus growth in the presence and absence of rifampicin
One-step growth experiments with 3 plaque-forming units
(PFU) of virus per cell were carried out to assess the effects of
the drug on virus yield. In each case, the mutant replicated
approximately 1.5 logs higher than the wild-type virus in the
presence of rifampicin (Fig. 4). The 21-h yields of seven mu-
tants and wild-type virus in the presence and absence of
rifampicin were determined in triplicate as shown in Fig. 5A.
The difference in virus yield between the wild-type and mutant
viruses was not statistically significant in the absence ofdays on BS-C-1 cell monolayers in 6-well plates by representative rifampicin-
100 μg per ml of rifampicin were visualized by staining with crystal violet and
Wild-type VACV strain WR is designated WR.
Fig. 4. One-step virus growth in the presence and absence of rifampicin. BS-C-1 cells were infected with 3 PFU per cell of wild-type VACVWR or mutants designated
by the codon substitution in the D13L gene. After the 1-h adsorption, the cells were incubated for 0, 8, 21 or 44 h in the absence (uninterrupted line) or presence
(dashed line) of 100 μg of rifampicin per ml. Virus titers were determined by plaque assay in the absence of rifampicin.
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between the wild-type virus and each of the mutants was highly
significant (p<0.005). The wild-type virus was inhibited by
98.7% under the latter conditions. We also followed the growth
of viruses when cells were infected with 0.33 PFU of virus per
cell. Even at this lower multiplicity of infection, where a growth
defect of mutant viruses might be more apparent, the yields
were similar in the absence of rifampicin (Fig. 5B). Moreover,
the yields of mutant viruses in the presence and absence of
rifampicin were very similar, whereas growth of wild-type virus
was inhibited by 98.3% (Fig. 5B).
Discussion
Our interest in the D13 protein of VACV stemmed from its
intriguing function as an essential component of the temporary
scaffold specifying the curvature of IVs, role as a target for the
drug rifampicin and high conservation among poxviruses. The
99–100% sequence identity of D13 amongst all orthopoxvirus
species suggested that the protein might not tolerate many
mutations without loss of function. The ability to select
rifampicin-resistant mutants provided us with an opportunity
to more thoroughly map the sites of rifampicin resistance, while
allowing us to determine the location of amino changes with
minimal effects on replication. Our strategy was to transfect
randomly PCR mutagenized D13L DNA into cells infected with
wild-type VACVand isolate plaques that formed in the presenceof rifampicin. In this manner, we isolated 63 drug-resistant
mutants and identified the codon changes by DNA sequencing.
Of these, 25 had single base changes that encoded amino acid
substitutions in D13L and 22 were unique. Each of the 22
mutations was shown to mediate drug resistance. We also
isolated five spontaneous rifampicin-resistant mutants and
found that four of these were unique with respect to the others.
Together with the six spontaneous mutants reported previously,
there are now a total of 32 changes in 24 amino acids of D13
known to confer rifampicin resistance. Seven of the 24 amino
acids cluster near the N-terminus (cluster 1, between amino
acids 17 and 33), four near the center of the protein (cluster 2,
between amino acids 222 and 243) and four near the C-terminus
(cluster 3, between amino acids 480 and 488). These sites were
also notable for the occurrence of multiple substitutions at the
same amino acid. The remaining eight amino acids were
distributed on the fringes of the clusters. Many of the mutations
were non-conservative, i.e., from a non-charged to a charged
amino acid or vice versa or a small to a bulky amino acid or vice
versa. However, a few changes were conservative such as
K17R, E465D and I485L. In view of the extreme conservation
of orthopoxvirus D13 homologs, we were surprised by the
fitness of the mutants. In the absence of rifampicin, the yields of
representative mutants from each of the clusters were similar to
those of wild-type virus. Their unimpaired replication accounts
for the ease of isolation of spontaneous rifampicin resistance
mutants, which we detected after one passage of individual
Fig. 5. Virus yields in the presence or absence of rifampicin. (A) BS-C-1 cells
were infected in triplicate with 3 PFU per cell of mutant or wild-type VACVWR
in the absence (−Rif) or presence (+Rif) of 100 μg of rifampicin per ml as
described in the legend to Fig. 4. After 21 h, virus yields were determined by
plaque assay in the absence of rifampicin. Standard error bars are shown. (B)
Cells were infected in duplicate as described in panel A except that the
multiplicity of infection was 0.33 PFU per cell and virus yields were determined
at 0, 21 and 44 h. Abbreviations for mutant and wild-type viruses are the same as
in Fig. 4.
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plaques in the presence of 100 μg per ml of rifampicin, the
resistant mutants made the same number of slightly smaller
plaques in the presence of drug. It is difficult to know whether
some of the size reduction is due to non-specific cellular effects
of the drug or to a weak effect on D13. Under one step growth
conditions in the presence of rifampicin, the yields of repre-
sentative viruses mapping to different regions of D13 were 1.5 to
2 logs higher than that of wild-type virus.
Rifampicin is a bacteriocidal antibiotic that is used to treat
tuberculosis and leprosy as well as other infections. It interferes
with transcription by binding to bacterial RNA polymerase.
Rifampicin resistance of Escherichia coli mutants map to the
center of the rpoB gene, affecting only a limited number of
amino acids that are thought to be present in a binding pocket(Jin and Gross, 1988). The concentration of rifampicin needed
to inhibit vaccinia virus replication is higher than that of bacteria
and the drug has not found clinical utility as an antiviral agent.
Although direct binding of rifampicin to D13 has not been
reported, that fact that all spontaneous VACV rifampicin-
resistant mutants map to D13 makes this likely. In contrast to
E. coli rpoB, D13 mutations that confer rifampicin resistance
form clusters at the two ends of the protein as well as in the
central region. Although speculative, we suggest that these
discontinuous regions of D13 form a rifampicin-binding
pocket. A segment of D13, between amino acids 71 to 195,
has a limited but statistically significant similarity with predicted
structural elements of the capsid proteins of iridoviruses and
phycodnaviruses (Iyer et al., 2001). The C-terminal jelly roll-
like domain of the capsid protein of the latter viruses is totally
absent from D13 and is replaced by a predicted β-strand-rich
domain without detectable structural similarity to a domain of
any other protein. Unfortunately, few of the rifampicin resistance
mutations map to the homology region and therefore the full
interpretation of our data must await structural analysis of D13.
Based on electron microscopic images of D13, we doubt that
rifampicin interferes with trimer formation and more likely
prevents interaction of D13 with a viral membrane protein
(Szajner et al., 2005).
Materials and methods
PCR mutagenesis
PCR mutagenesis of the D13L gene in plasmid pJAG9.4 (a
gift of P. Szajner) was carried out using theGeneMorph Random
Mutagenesis Kit (Stratagene) according to the manufacturers
direction to achieve 0 to 3 mutations per kbp. For mutagenesis of
the entire D13L gene, the primer pair used was 5′ CTATGAA-
GATAAGGAAAAGGTC 3′ and 5′ TAGCTCCGTATTCCA-
GACT 3′. To enrich for mutations downstream of the N-terminal
cluster, the oligonucleotide 5′ ATATATGCCGCAATATATT-
TCTC 5′was used in place of the first primer. DNAwas purified
using the QIAquick PCR Purification kit (Qiagen).
Isolation and sequencing of rifampicin-resistant mutants
BS-C-1 cells in individual wells of a 6-well plate were
infected at a multiplicity of 1 PFU per cell and 1 h later were
transfected with 0.5 to 1.0 μg of PCR product described above.
Each well received DNA from an independent PCR reaction.
After 21 h, the cells were harvested and lysed by freezing and
thawing. Stock solutions of 10 mg/ml of rifampicin (Sigma-
Aldrich, St. Louis, MO) were prepared in DMSO and stored at
−20 °C or −80 °C for use at a 100-fold dilution. Dilutions of the
lysates were incubated with BS-C-1 cells for 1 h. The plates
were washed and covered with a 1% agarose (low melting point,
Invitrogen) overlay containing 100 μg of rifampicin per ml at
37 °C for 2 days. Virus from individual plaques was then
subjected to a second round of plaque purification under
the same conditions. The cloned rifampicin-resistant viruses
were amplified in a 24-well plate and the DNA isolated with a
232 J.C. Charity et al. / Virology 359 (2007) 227–232QIAamp DNA blood mini kit (Qiagen). Amplicons, prepared
from each DNA preparation, were sequenced using an ABI
PRISM 3100 Genetic Analyzer.
To isolate spontaneous rifampicin-resistant mutants, 5
plaques of wild-type VACV WR were amplified separately in
a 6-well plate and harvested. Dilutions of virus from the single
round of amplification were used to infect 6-well plates of BS-
C-1 cells covered by an agarose overlay containing 100 μg of
rifampicin per ml. Virus from individual plaques was subjected
to a second round of plaque purification. The cloned rifampicin
resistance virus was then amplified and the DNA sequenced as
above.
Verification of rifampicin resistance mutations by site-specific
mutagenesis
The Quickchange site-directed mutagenesis kit (Stratagene)
was used to introduce specific mutations into the D13L gene in
pJAG9-4. BS-C-1 cells were infected with 109 PFU of VACV
WR. After 1 h, the cells were transfected with 1 μg of plasmid.
The cells were harvested approximately 26 h later and disrupted
by freezing and thawing. Dilutions of the lysate were then
titered in the presence of 100 μg of rifampicin per ml and
plaques were visualized by staining the plates with crystal violet
(0.1% in 20% ethanol) and washing with water.
Determination of virus yields in the presence and absence of
rifampicin
BS-C-1 cell monolayers in 6-well plates were infected with
0.2 ml of virus at a multiplicity of 0.33 or 3 PFU per cell. After
1 h at 37 °C, the plates were washed and 2 ml of medium
containing 2.5% bovine serum with or without 100 μg per ml of
rifampicin was added. The cells were harvested at various times
and lysed by freezing and thawing three times and sonicating.
Virus dilutions were adsorbed to BS-C-1 cells for 1 h, covered
with an overlay of 0.5% methyl cellulose (Sigma-Aldrich) in
minimum essential medium with Earle's salts (Quality
Biologicals) and incubated for 2 days at 37 °C. Virus plaques
were visualized by staining with crystal violet.
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